Børresen-Dale AL - Search Results

1

Mutations and polymorphisms of the p21B transcript in breast cancer.

Knappskog S, Chrisanthar R, Staalesen V, Børresen-Dale AL, Gram IT, Lillehaug JR, Lønning PE. Knappskog S, et al. Int J Cancer. 2007 Aug 15;121(4):908-10. doi: 10.1002/ijc.22777. Int J Cancer. 2007. PMID: 17443496

2

Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome.

Aas T, Geisler S, Paulsen T, Børresen-Dale AL, Varhaug JE, Lønning PE, Akslen LA. Aas T, et al. Acta Oncol. 1996;35 Suppl 5:5-8. doi: 10.3109/02841869609083960. Acta Oncol. 1996. PMID: 9142957

3

Screening for ESR mutations in breast and ovarian cancer patients.

Anderson TI, Wooster R, Laake K, Collins N, Warren W, Skrede M, Elles R, Tveit KM, Johnston SR, Dowsett M, Olsen AO, Møller P, Stratton MR, Børresen-Dale AL. Anderson TI, et al. Hum Mutat. 1997;9(6):531-6. doi: 10.1002/(SICI)1098-1004(1997)9:6<531::AID-HUMU6>3.0.CO;2-4. Hum Mutat. 1997. PMID: 9195227

4

Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.

Ellis PA, Lonning PE, Borresen-Dale A, Aas T, Geisler S, Akslen LA, Salter I, Smith IE, Dowsett M. Ellis PA, et al. Br J Cancer. 1997;76(4):480-5. doi: 10.1038/bjc.1997.413. Br J Cancer. 1997. PMID: 9275025 Free PMC article.

5

Interaction between bcl-2 and p21 (WAF1/CIP1) in breast carcinomas with wild-type p53.

Bukholm IK, Nesland JM, Kåresen R, Jacobsen U, Børresen-Dale AL. Bukholm IK, et al. Int J Cancer. 1997 Sep 26;73(1):38-41. doi: 10.1002/(sici)1097-0215(19970926)73:1<38::aid-ijc7>3.0.co;2-2. Int J Cancer. 1997. PMID: 9334807

6

CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1.

Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lønning PE, Erikstein B, Kåresen R, Gabrielsen OS, Børresen-Dale AL. Nedelcheva Kristensen V, et al. Cancer Res. 1999 Jun 15;59(12):2825-8. Cancer Res. 1999. PMID: 10383140

7

Genetic variants of CYP19 (aromatase) and breast cancer risk.

Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Kåresen R, Kristensen T, Børresen-Dale AL. Kristensen VN, et al. Oncogene. 2000 Mar 2;19(10):1329-33. doi: 10.1038/sj.onc.1203425. Oncogene. 2000. PMID: 10713674

8

Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma.

Stokke T, Galteland E, Holte H, Smedshammer L, Suo Z, Smeland EB, Børresen-Dale AL, DeAngelis P, Steen HB. Stokke T, et al. Int J Cancer. 2000 Jul 20;89(4):313-24. doi: 10.1002/1097-0215(20000720)89:4<313::aid-ijc1>3.0.co;2-d. Int J Cancer. 2000. PMID: 10956404

9

Screening breast cancer patients for Norwegian ATM mutations.

Laake K, Vu P, Andersen TI, Erikstein B, Kåresen R, Lonning PE, Skovlund E, Børresen-Dale AL. Laake K, et al. Br J Cancer. 2000 Dec;83(12):1650-3. doi: 10.1054/bjoc.2000.1519. Br J Cancer. 2000. PMID: 11104561 Free PMC article.

10

Enhanced detection of mutations in BRCA1 exon 11 using restriction endonuclease fingerprinting-single-strand conformation polymorphism.

Jugessur A, Frost P, Andersen TI, Steine S, Lindblom A, Børresen-Dale AL, Eiken HG. Jugessur A, et al. J Mol Med (Berl). 2000;78(10):580-7. doi: 10.1007/s001090000147. J Mol Med (Berl). 2000. PMID: 11199332

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

511 results

Search Page

Filters